Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations – Appraisal Consultation Document

In DRAFT guidance, NICE does not recommend pemigatinib for locally advanced or metastatic cholangiocarcinoma with FGFR2 alterations after systemic therapy as the most likely cost-effectiveness estimates are higher than what NICE considers a cost-effective use of NHS resources.

National Institute for Health and Care Excellence